Bayer's Financial Performance in Q4 and Full-Year 2024

Bayer AG has disclosed its financial outcomes for the fourth quarter of fiscal 2024, revealing a 1% decrease in sales to €11.7 billion. The company's full-year sales also saw a decline, dropping by 2.2% to €46.6 billion.

EBITDA and Net Income Insights

With an EBITDA of €1.9 billion for the quarter and €8.7 billion for the year, Bayer highlighted an improvement in net income compared to the previous quarter, achieving €1.3 billion or €1.36 per share. However, the fiscal year 2024 concluded with a net loss of €2.9 billion or €2.99 per share.

Looking Ahead to 2025

Bayer anticipates its net sales for the full year of 2025 to range between €45 and €47 billion. The company's report also cautions about the potential impact of geopolitical uncertainties, including tariffs and additional foreign exchange fluctuations, on its future performance.

Reflecting on a Challenging Year

"2024 was a challenging year for Bayer, characterized by volatile business dynamics. The Supervisory Board concentrated on the company's strategic alignment and addressing problem areas, such as ongoing litigations in the United States, the company's high leverage ratio, and the further development of the pharmaceutical pipeline," the report concluded.